Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/22/2026

1. SPCX
2. NVDA
3. NFLX
4. META
5. TSLA
6. ISRG
7. SMCI
8. GOOGL
9. RTX
10. S

Go back to Aquestive Therapeutics, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Business Highlights

Aquestive Therapeutics (AQST) PT Lowered to $21 at BMO Capital

March 15, 2019 6:51 AM EDT

BMO Capital analyst Gary Nachman lowered the price target on Aquestive Therapeutics (NASDAQ: AQST) to $21.00 (from $24.00) while maintaining a Outperform rating following relatively in-line 4Q18 results.

guidance is appropriately conservative and should be very achievablemanagement sounded confident in several potential nondilutive financing options

... More

Aquestive Therapeutics Inc. (AQST) Misses Q4 EPS by 5c, Revenues Beat; Offers FY19 Revenue Below Guidance

March 14, 2019 7:12 AM EDT

Aquestive Therapeutics Inc. (NASDAQ: AQST) reported Q4 EPS of ($0.56), $0.05 worse than the analyst estimate of ($0.51). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $16.69 million.

"Aquestive made significant progress in 2018 by launching our first proprietary product and continuing our transformation into a... More